This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 4
  • /
  • Phase III EMBARK trial of Xtandi plus leuprolide i...

Phase III EMBARK trial of Xtandi plus leuprolide in prostate cancer presented at 2023 American Urological Association Annual Meeting.- Astellas Pharma and Pfizer

Read time: 1 mins
Published:30th Apr 2023

Astellas Pharma and Pfizer Inc. announced that Xtandi (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide (Hazard Ratio [HR]: 0.42; 95% Confidence Interval [CI], 0.30–0.61; P<0.0001), as assessed by the primary endpoint of metastasis-free survival (mfs), in men with non-metastatic hormone-sensitive prostate cancer (nmhspc; also known as non-metastatic castration-sensitive prostate cancer or nmcspc) with high-risk biochemical recurrence (bcr).

These data from the phase iii embark trial, which evaluated patients across three study arms (xtandi plus leuprolide [n="355]," placebo plus leuprolide [n="358]," or xtandi monotherapy [n="355])," were presented as a plenary session during the 2023 american urological association annual meeting.></0.0001),>

The overall safety profile was consistent with the known safety profile of each of the medicines. The most common adverse events in those treated with Xtandi plus leuprolide were fatigue, hot flush, and arthralgia and in those treated with Xtandi monotherapy were fatigue, gynecomastia, and arthralgia.

Consistent with the study’s primary endpoint, statistically significant and clinically meaningful improvements were also observed in the trial’s key secondary endpoints in both the Xtandi combination and monotherapy arms. Specifically, the Xtandi monotherapy arm demonstrated that treatment with Xtandi reduced the risk of metastasis or death by 37% versus leuprolide plus placebo (HR: 0.63; 95% CI, 0.46–0.87; P=0.0049), meeting its MFS endpoint. Treatment with Xtandi plus leuprolide and XTANDI monotherapy reduced the risk of PSA progression by 93% (HR: 0.07; 95% CI, 0.03–0.14; P<0.0001) and 67% (hr: 0.33; 95% ci, 0.23–0.49; p><0.0001), respectively, versus placebo plus leuprolide. the progression risk in starting a new antineoplastic therapy was reduced by 64% in those treated with xtandi plus leuprolide (hr: 0.36; 95% ci, 0.26–0.49; p><0.0001) and 46% in those treated with xtandi monotherapy (hr: 0.54; 95% ci, 0.41–0.71; p><0.0001) versus placebo plus leuprolide. a positive trend in the key secondary endpoint of overall survival (os) was also observed in the xtandi combination arm at the time of the analysis, but these data were not yet mature. patients in the trial will be followed for a subsequent final os analysis. detailed results from the trial will be submitted for peer-reviewed publication.></0.0001)></0.0001)></0.0001),></0.0001)>

Condition: Prostate Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.